PTGDS and infection: In addition, treatment with the DP1 inhibitors S5751 and MK-0524 and L-PGDs inhibitors AT-56 and CAY10678 increased the expression of PAFR (Figure 1A) and MMP-2 (Figure 1B) during infection (P < 0.05).